Effects of Customized Insoles for Individuals With Symptomatic Hallux Valgus
Launched by UNIVERSIDADE FEDERAL DO RIO GRANDE DO NORTE · Jun 2, 2022
Trial Information
Current as of July 24, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating the effects of customized insoles on people with a foot condition called hallux valgus, which is a common deformity that causes the big toe to lean towards the other toes, often leading to pain and difficulty walking. The study aims to see if these specially designed insoles can help reduce pain and improve the ability to walk or perform daily activities. While some previous research suggests that using insoles, especially when paired with toe separators, can help alleviate pain, there is still no clear agreement on the best type of insole or how long it should be worn for the best results.
To participate in the trial, individuals must be over 18 years old and have mild to moderate hallux valgus, with pain levels between 3 and 8 on a simple scale. Participants will need to wear the insoles for at least 4 hours a day and use closed-toed shoes. However, those currently undergoing physical therapy for hallux valgus or with certain medical conditions, such as rheumatoid arthritis or recent foot injuries, won't be eligible. If you join the study, you can expect to regularly evaluate how the insoles affect your pain and foot function over time. This research could help improve treatment options for many people experiencing this common foot issue.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Individuals of both sexes aged over 18 years;
- • Presence of mild to moderate hallux valgus, according to the Manchester scale;
- • Presenting no hallux with intensity greater than or equal to 3 points up to 8 points, according to the Numerical Pain Scale (END);
- • Be available to actively use the insole for at least 4 hours/day;
- • Commitment to wear closed shoes, for example (sneakers, shoes used by the patient, due to: wide toe cap and heel height of 2 to 3 cm) during the study.
- Exclusion Criteria:
- • Being in physical therapy treatment for hallux valgus concomitantly with the research;
- • Previous hallux valgus surgeries performed in the last 5 years;
- • Presence of foot wounds and wounds, dislocations or metatarsophalangeal fractures in the foot with HV, in the last 5 years
- • Presence of diseases such as rheumatoid arthritis, decompensated diabetes, gout, neurodegenerative diseases;
- • Cognitive and mental disorder being unable to respond; those related to the study
About Universidade Federal Do Rio Grande Do Norte
The Universidade Federal do Rio Grande do Norte (UFRN) is a prestigious Brazilian institution dedicated to advancing education, research, and innovation in various fields, including health sciences. As a clinical trial sponsor, UFRN leverages its robust academic and research capabilities to contribute to the development of effective medical interventions and therapies. The university fosters collaborative partnerships with healthcare professionals, researchers, and industry stakeholders, ensuring that clinical trials conducted under its auspices adhere to the highest ethical standards and regulatory requirements. UFRN is committed to enhancing public health outcomes through rigorous scientific inquiry and the translation of research findings into clinical practice.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Natal, Rn, Brazil
Patients applied
Trial Officials
Marcelo C de Souza, PT, PhD
Principal Investigator
Universidade Federal do Rio Grande do Norte
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials